Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1 (currently amended) A method of maintaining The use of NIV23 protein to maintain undifferentiated biological cells in culture comprising culturing the cells the presence of NIV23 protein.
- 2 (currently amended) The use according to method of claim 1, wherein the NM23 protein acts as a survival factor for cultured cells.
- 3 (currently amended) The use according to method of claim 1, wherein the NM23 acts to prevent differentiation and maturation of cultured cells.
- 4 (currently amended) The use according to method of claim 1, wherein the cultured cells are selected from the group comprising stem cells and precursor cells.
- 5 (currently amended) The use according to method of claim 1, wherein the cultured cells are for the rapeutic use.
- 6 (currently amended) The use according to method of claim 1, wherein the cultured cells are for non therapeutic use.
- 7 (currently amended) The use according to method of claim 1, wherein the cultured cells are selected from the group comprising mesenchymal cells, haematopoietic cells, cells of the central nervous system (CNS) and epidermal cells.
- 8 (currently amended) The use according to method of claim 1, wherein the cells are collected from the blood or bone marrow.
- 9 (original) A method of preparing a biological cell for therapeutic use, the method comprising the consecutive or concurrent steps of:
 - i) culturing the biological cell in the presence of NM23 protein; and

- ii) adapting the biological cell for therapeutic use.
- 10 (original) A method of therapy, the method comprising the consecutive or concurrent steps of:
 - i) obtaining a biological cell;
 - ii) culturing the biological cell in the presence of NM23 protein; and
- iii) adapting the biological cell for therapeutic use and further comprising administering the adapted biological cell to a subject in need of such therapy.
- 11 (original) The method of claim 9 or claim 10, wherein the biological cell is a stem cell.
- 12 (original) The method of claim 9 or claim 10, wherein the biological cells is a progenitor cell.
- 13 (previously presented) The method of claim 9 or 10, wherein the adaptation for therapeutic use comprises *ex vivo* expansion of biological cell numbers.
- 14 (previously presented) The method of claim 9 or 10, wherein the biological cell is selected from the group comprising mesenchymal cells, haematopoietic cells, cells of the central nervous system (CNS) and epidermal cells.
- 15 (previously presented) The method of claim 9 or 10, wherein the cells are collected from the blood or bone marrow.
- 16 (previously presented) The method of claim 9 or 10, wherein the adaptation for therapeutic use is an adaptation for use in gene therapy.
- 17 (previously presented) The method of claim 9 or 10, wherein the adaptation for therapeutic use is an adaptation for use in stem cell therapy.
- 18 (previously presented) The method of claim 9 or 10, wherein the adaptation for therapeutic use is an adaptation for use in immunotherapy.
- 19 (previously presented) The method of claim 9 or 10, wherein the adaptation for therapeutic use comprises *ex vivo* expansion of biological cell numbers.
- 20 (previously presented) The method of claim 9 or 10, wherein the biological cell is selected from the group comprising mesenchymal cells, haematopoietic cells, cells of the

central nervous system (CNS) and epidermal cells.

- 21 (previously presented) The method of claim 9 or 10, wherein the cells are collected from the blood or bone marrow.
- 22 (original) A cell culture medium for the promotion of cell survival in culture without differentiation, the medium being supplemented with NM23 protein.
- 23 (original) A culture medium according to claim 22, wherein the cells to be cultured are selected from the group comprising mesenchymal cells, haematopoietic cells, cells of the central nervous system (CNS) and epidermal cells.
- 24 (original) A culture medium according to claim 22, wherein the cells to be cultured are collected from the blood or bone marrow.
- 25 (previously presented) A culture medium according to claim 22, wherein the medium comprises RPMI 1640 medium.
- 26 (previously presented) A culture medium according to claim 22, wherein the medium comprises DMEM medium.